|
Invited Speakers:
|
|
Anton Beletskii, Ph.D., Cell Biologist, Molecular and Cell Biology Laboratory, General Electric
Steven Charlton, Novartis
Peter Fürst, Ph.D. (Keynote Speaker), Head Basel Screening Operation, Novartis Institutes for Biomedical Resarch
Jon Hawkinson, Principal Scientist, Elan Pharmaceuticals
Ron Johnson, Ph.D., NHGRI, NIH
John Morin, Director HTS, Wyeth Research
Jonathan O'Connell, Associate Director, Lead Discovery, Bristol-Myers Squibb
Jefferson Paslay (Keynote Speaker), Vice President, Screening Sciences, Wyeth Research
Matt Peters, AstraZeneca Pharmaceuticals
Frank Stuhmeier, Ph.D., Senior Principle Scientist, Pfizer, Inc.
Jun Xian, Assistant Director, Harvard University
Dominique Perrin, Group Leader, Biochemical Pharmacology, Serono Pharmaceutical Research Institute
Susan Pratt, Eli Lilly & Co.
Laura DeForge, Ph.D., Senior Scientist, Genentech, Inc.
Frederick Monsma, Director, New Lead Discovery, Schering-Plough Research Institute Michael Weber, Merck & Co.
Karl Salzwedel, Head of High-Throughput Drug Discovery, Panacos Pharmaceuticals
Tara Stauffer, Pharmacopeia Drug Discovery, Inc. Christopher Heise, Scientist II, Dept. of Discovery Biology, Neurocrine Biosciences
Yaya Liu, Abbott Laboratories
|
|